Company intelligence / Profile preview

Readline Biotech

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Readline Biotech is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of innovative small molecule drugs through targeted protein degradation (TPD) technology. The company leverages its proprietary PROTAC (Proteolysis-Targeting Chimera) platform to address previously undruggable targets in oncology and other serious diseases. Its lead programs focus on hormone-driven cancers, such as prostate and breast cancer, as well as difficult-to-treat mutations like KRAS. Readline Biotech aims to provide next-generation therapeutic solutions by efficiently eliminating disease-causing proteins rather than simply inhibiting them.

Therapeutic areas: Oncology
Modalities: Small moleculePROTACProteolysis-targeting chimera therapy
Industry: Biotech

Beyond the preview

Go deeper on Readline Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Readline Biotech.

Explore the full profile